Anne Lok

531 total citations
21 papers, 243 citations indexed

About

Anne Lok is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Anne Lok has authored 21 papers receiving a total of 243 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 11 papers in Hematology and 6 papers in Molecular Biology. Recurrent topics in Anne Lok's work include Multiple Myeloma Research and Treatments (6 papers), Lymphoma Diagnosis and Treatment (6 papers) and Protein Degradation and Inhibitors (6 papers). Anne Lok is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Lymphoma Diagnosis and Treatment (6 papers) and Protein Degradation and Inhibitors (6 papers). Anne Lok collaborates with scholars based in France and Canada. Anne Lok's co-authors include Philippe Moreau, Benoît Tessoulin, Steven Le Gouill, Cyrille Touzeau, Beatrice Mahé, Viviane Dubruille, Nicolas Blin, Thomas Gastinne, Pierre Péterlin and Thierry Guillaume and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Annals of Oncology.

In The Last Decade

Anne Lok

20 papers receiving 242 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anne Lok France	10	130	108	76	62	43	21	243
Shin‐ichi Fuchida Japan	11	107 0.8×	169 1.6×	87 1.1×	37 0.6×	25 0.6×	38	294
Emily Heath Germany	4	88 0.7×	103 1.0×	89 1.2×	42 0.7×	26 0.6×	6	241
Hira Shaikh United States	8	101 0.8×	71 0.7×	58 0.8×	34 0.5×	30 0.7×	48	218
Sushrut Patil Australia	10	66 0.5×	98 0.9×	68 0.9×	60 1.0×	78 1.8×	35	292
Ioannis Baltadakis Greece	9	77 0.6×	98 0.9×	42 0.6×	34 0.5×	64 1.5×	17	232
José L. Ochoa-Bayona United States	9	168 1.3×	210 1.9×	110 1.4×	74 1.2×	63 1.5×	40	371
Alicia Bailén Spain	7	137 1.1×	131 1.2×	35 0.5×	71 1.1×	13 0.3×	12	256
Diego Carbonell Spain	11	56 0.4×	116 1.1×	41 0.5×	25 0.4×	50 1.2×	31	258
Ulrich Duehrsen Germany	7	125 1.0×	85 0.8×	43 0.6×	99 1.6×	15 0.3×	32	243
Anna Sicuranza Italy	11	94 0.7×	142 1.3×	73 1.0×	45 0.7×	54 1.3×	40	295

Countries citing papers authored by Anne Lok

Since Specialization

Citations

This map shows the geographic impact of Anne Lok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Lok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Lok more than expected).

Fields of papers citing papers by Anne Lok

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Lok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Lok. The network helps show where Anne Lok may publish in the future.

Co-authorship network of co-authors of Anne Lok

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Lok. A scholar is included among the top collaborators of Anne Lok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Lok. Anne Lok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bourgeois, Amandine Le, Marianne Coste‐Burel, Pierre Péterlin, et al.. (2022). B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 28(5). 279.e1–279.e4. 9 indexed citations

Chevallier, Patrice, Marianne Coste‐Burel, Amandine Le Bourgeois, et al.. (2021). Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients. SHILAP Revista de lepidopterología. 2(3). 520–524. 25 indexed citations

Gastinne, Thomas, Amandine Le Bourgeois, Marianne Coste‐Burel, et al.. (2021). Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy. Blood. 138(Supplement 1). 254–254. 3 indexed citations

Lok, Anne, Benoît Tessoulin, Thomas Gastinne, et al.. (2020). Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life. Annals of Hematology. 99(7). 1595–1604. 30 indexed citations

Garnier, Alice, Thierry Guillaume, Pierre Péterlin, et al.. (2020). Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide. Annals of Hematology. 99(6). 1341–1350. 8 indexed citations

Tessoulin, Benoît, Nicolas Blin, Thomas Gastinne, et al.. (2019). Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study. Annals of Hematology. 98(6). 1441–1447. 11 indexed citations

Tessoulin, Benoît, Catherine Pellat‐Deceunynck, Martine Amiot, et al.. (2019). The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. BMC Cancer. 19(1). 855–855. 7 indexed citations

Tessoulin, Benoît, Beatrice Mahé, Viviane Dubruille, et al.. (2019). Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study. Annals of Hematology. 98(6). 1435–1440. 23 indexed citations

Guillaume, Thierry, Pierre Péterlin, Alice Garnier, et al.. (2019). Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies. Biology of Blood and Marrow Transplantation. 25(7). 1465–1471. 2 indexed citations

10.

Tessoulin, Benoît, Beatrice Mahé, Viviane Dubruille, et al.. (2019). PB2146 SINGLE AGENT DARATUMUMAB IN VERY ADVANCED RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A REAL‐LIFE SINGLE CENTER RETROSPECTIVE STUDY. HemaSphere. 3(S1). 965–966.

11.

Bodet‐Milin, Caroline, Clément Bailly, Thierry Guillaume, et al.. (2018). Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients. Biology of Blood and Marrow Transplantation. 25(5). 906–911. 3 indexed citations

12.

Péterlin, Pierre, Thierry Guillaume, Alice Garnier, et al.. (2018). Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases. Leukemia Research Reports. 9. 16–17. 1 indexed citations

13.

Lok, Anne, Géraldine Descamps, Benoît Tessoulin, et al.. (2018). p53 regulates CD46 expression and measles virus infection in myeloma cells. Blood Advances. 2(23). 3492–3505. 20 indexed citations

14.

Lok, Anne, Thomas Gastinne, Beatrice Mahé, et al.. (2018). Progression of disease within 2 years (POD24) is a clinically significant endpoint to identify follicular lymphoma patients with high risk of death. Annals of Oncology. 29. viii364–viii364. 1 indexed citations

15.

Chevallier, Patrice, Pierre Péterlin, Alice Garnier, et al.. (2018). Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies. Oncotarget. 9(71). 33528–33535. 10 indexed citations

16.

Tessoulin, Benoît, Thomas Gastinne, Philippe Moreau, et al.. (2017). Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas. Annals of Hematology. 96(6). 943–950. 9 indexed citations

17.

Tessoulin, Benoît, Marion Eveillard, Anne Lok, et al.. (2017). p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell. Blood Reviews. 31(4). 251–259. 36 indexed citations

18.

Lok, Anne, Géraldine Descamps, Benoît Tessoulin, et al.. (2016). The Oncolytic Measles Virus Preferentially Infects p53 Abnormal Myeloma Cells. Blood. 128(22). 310–310. 1 indexed citations

19.

Mahé, Beatrice, Nicolas Blin, Viviane Dubruille, et al.. (2015). Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study. Annals of Oncology. 27(2). 314–318. 31 indexed citations

20.

Lok, Anne, et al.. (2014). Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma. Haematologica. 99(3). e33–e34. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact